OncRef

Clinical Trial: NCT02446457

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-03-09

Study Overview

Brief Summary

This phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement. Immunotherapy with monoclonal antibodies, such as rituximab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rutuximab with pembrolizumab and lenalidomide may work better at treating follicular lymphoma and diffuse large B-cell lymphoma.

Official Title

Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma

Conditions

Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma

Intervention / Treatment

  • Other: Laboratory Biomarker Analysis
  • Drug: Lenalidomide
  • Biological: Pembrolizumab
  • Biological: Rituximab

Other Study ID Numbers

  • 2014-0539
  • NCI-2015-01307
  • 2014-0539

Start Date (Actual)

2015-07-31

Primary Completion Date (Actual)

2025-03-31

Study Completion Date (Estimated)

2026-04-30

Enrollment (Actual)

53

Study Type

Interventional

Phase

Phase 2